Acute encephalopathy with combination dabrafenib/trametinib therapy-Reference-Cited by-同舟云学术

Acute encephalopathy with combination dabrafenib/trametinib therapy

Published:2016-03-16 Issue:4 Volume:23 Page:313-317
ISSN:1078-1552
Container-title:Journal of Oncology Pharmacy Practice
language:en
Short-container-title:J Oncol Pharm Pract

Author:

Cooper Jalyn¹,Kodali Dheeraj²,Higa Gerald M¹²

Affiliation:

1. School of Pharmacy, Department of Clinical Pharmacy West Virginia University, Morgantown, WV, USA

2. School of Medicine, Section of Hematology/Oncology, Department of Clinical Pharmacy West Virginia University, Morgantown, WV, USA

Abstract

Biomarkers have improved the clinical application of numerous targeted agents used to treat solid tumors. In melanoma, the finding that approximately 60% of tumor cells harbor specific Val600 mutations of BRAF has increased the likelihood of response to certain agents aimed at inhibiting the mutant kinase. While dabrafenib is an effective anti-tumor agent with acceptable tolerability in patients with BRAF-mutated melanoma, we report the development (and outcome) of a previously unpublished acute toxic reaction observed in a patient receiving the drug.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1078155216638551

Reference15 articles.

1. Durable Complete Responses With High-Dose Bolus Interleukin-2 in Patients With Metastatic Melanoma Who Have Experienced Progression After Biochemotherapy

2. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

3. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

4. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example;Journal of Oncology Pharmacy Practice;2024-01-22

2. Fatal encephalopathy with brainstem involvement under dabrafenib and trametinib in a BRAF-positive metastatic melanoma;Revue Neurologique;2021-11

3. BRAF Inhibitor Therapy-Related Encephalitis in a Patient with Metastatic Melanoma;The Oncologist;2021-07-17

4. Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2019-12-09

5. Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome;Annals of Oncology;2019-06